Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accord Rolls Out Zercepac Trastuzumab Biosimilar In UK

Rival To Herceptin Was Developed By China’s Shanghai Henlius Biotech

Executive Summary

Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.

You may also be interested in...



Accord And Henlius Broaden Trastuzumab Alliance

Shanghai Henlius Biotech and Accord Healthcare have broadened their collaboration on trastuzumab, with the Chinese company licensing its Zercepac biosimilar to Accord in the US and Canada. Meanwhile, Accord has launched a Pelgraz pegfilgrastim pre-filled injector and patient app in the UK.

Henlius’ Trastuzumab Approved In China

Shanghai Henlius Biotech has received the first Chinese approval for a trastuzumab biosimilar version of Herceptin.

Accord Adds To Crowded EU Trastuzumab Market

Shanghai Henlius Biotech is to make history with the first China-developed monoclonal antibody biosimilar in Europe, the firm’s Zercepac (trastuzumab) biosimilar that has been licensed to Accord Healthcare.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel